Scholarlink

<p>Hepatitis B virus (HBV) infection remains a leading cause of hepatocellular carcinoma (HCC) worldwide, particularly in East Asia. Liver cancer stem cells (LCSCs) have emerged as crucial drivers of HCC initiation, metastasis, recurrence, and therapeutic resistance. Accumulating evidence indicates that HBV, especially through its X protein (HBx), promotes LCSC formation and maintenance via activation of multiple oncogenic and stemness-related signaling pathways, including IL-6/STAT3, Wnt/β-catenin, Hippo, and Notch. Furthermore, HBV infection induces cellular plasticity through epithelial–mesenchymal transition (EMT), dedifferentiation, and metabolic reprogramming, facilitating the acquisition of stem-like phenotypes. Within the immunosuppressive tumor microenvironment shaped by chronic HBV infection, LCSCs gain enhanced immune evasion capabilities and interact with immune cells to sustain their niche. These interactions, coupled with metabolic and epigenetic alterations, underlie the profound resistance of LCSCs to conventional therapies. This review summarizes the current understanding of the molecular crosstalk between HBV infection and LCSC regulation, highlighting key pathways and mechanisms. We also discuss emerging therapeutic strategies targeting HBV-driven LCSCs, including combined antiviral and immunotherapy approaches, and underscore the need for further translational studies to improve outcomes in HBV-associated HCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The role of HBV in reprogramming liver cancer stem cells and shaping their plasticity and therapeutic vulnerabilities

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月3日

查看全文
  • Hanlin Gao,
  • Zhuoyan Lei,
  • Luye Wang,
  • Yumo Li,
  • Zhi Chen,
  • Gang Wang

摘要

Hepatitis B virus (HBV) infection remains a leading cause of hepatocellular carcinoma (HCC) worldwide, particularly in East Asia. Liver cancer stem cells (LCSCs) have emerged as crucial drivers of HCC initiation, metastasis, recurrence, and therapeutic resistance. Accumulating evidence indicates that HBV, especially through its X protein (HBx), promotes LCSC formation and maintenance via activation of multiple oncogenic and stemness-related signaling pathways, including IL-6/STAT3, Wnt/β-catenin, Hippo, and Notch. Furthermore, HBV infection induces cellular plasticity through epithelial–mesenchymal transition (EMT), dedifferentiation, and metabolic reprogramming, facilitating the acquisition of stem-like phenotypes. Within the immunosuppressive tumor microenvironment shaped by chronic HBV infection, LCSCs gain enhanced immune evasion capabilities and interact with immune cells to sustain their niche. These interactions, coupled with metabolic and epigenetic alterations, underlie the profound resistance of LCSCs to conventional therapies. This review summarizes the current understanding of the molecular crosstalk between HBV infection and LCSC regulation, highlighting key pathways and mechanisms. We also discuss emerging therapeutic strategies targeting HBV-driven LCSCs, including combined antiviral and immunotherapy approaches, and underscore the need for further translational studies to improve outcomes in HBV-associated HCC.